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Head and neck cancer is one of the most common cancers 
in Pakistan. Most of the patients present in advance stage. 
Laryngeal cancers account for 13% of head and neck 
cancer patients in our institution. Most of the advance 
laryngeal cancer patients treated with chemoradiation have 
poor quality of life due to poor function of the preserved 
larynx, ultimately needing salvage laryngectomy. 
Therefore, total laryngectomy followed by adjuvant 
radiotherapy remains the standard of care in T4 laryngeal 
cancer patients. Conventional radiotherapy techniques 
result in increased acute as well as long-term toxicity 
which impairs the quality of life, note ably xerostomia.[1]
Simultaneous integrated boost intensity-modulated 
radiation therapy (IMRT) is an advance radiotherapy 
technique allowing sparing of organs at risk (OAR) 
while giving high and homogenous dose to the primary 
target. It allows shorter overall treatment time with 
hypofractionation and dose escalation to primary disease 
with high biological equivalent dose (BED). In developing 
countries, it serves to spare the resources in terms of 
equipment usage in shorter fractionations, providing 
equivalent local control with reduced toxicity profile.[2,3]
A case of laryngeal carcinoma treated with total 
laryngectomy followed by adjuvant radiotherapy of 60 Gy 
in 30 fractions was treated with simultaneous integrated 
boost IMRT technique. A 66-year-old male patient 
presented to an ENT clinic with an 8-month history of 
hoarseness of voice. Biopsy revealed well-differentiated 
squamous cell carcinoma. Staging computed tomography 
(CT) neck with contrast showed glottic tumour associated 
with supra and subglottic extension. There was no 
regional lymphadenopathy. The patient was planned for 
total laryngectomy. Histopathology showed moderately 
differentiated squamous cell carcinoma, 3.5 cm in size, 
invading through thyroid cartilage and focally invaded 
soft tissue of neck (pT4a), margins free of tumour, no 
lymphovascular invasion or perineural invasion. No 
subglottic extension seen. 1 of 47 lymph nodes was 
positive. He had nutritional and dental assessment before 
radiotherapy.
CT for radiotherapy treatment planning was done with 
patient positioned supine, immobilized with a thermoplastic 
mask with neck in extended position. CT images of 3 mm 
slice thickness were acquired from vertex to carina. 
The clinical target volume was drawn on each CT slice 
using information from pre-operative imaging, operation 
notes and discussion with surgeon including sites at risk 
of microscopic disease. The CTV50 included areas of 
subclinical disease -the bilateral level Ib-V neck nodes. 
CTV60 included the tumour BED alone. PTV50 and 
PTV60 were formed by giving 5 mm margin to CTV50 and 
CTV60, respectively, as shown in Figures 1 and 2. OARs 
outlined included the brainstem, spinal cord, parotid glands, 
bilateral temporomandibular joint (TMJ) and cochlea.
Simultaneous integrated boost IMRT technique was used 
for treatment planning. PTV60 received 2.0 Gy daily dose 
up to 30 fractions while PTV50 received a daily dose of 
1.8 Gy up to 30 fractions. The dose constraints for OARs 
were as follows: 40 Gy maximum point dose to brainstem, 
maximum point dose of 40 Gy to spinal cord, mean dose 
<30 Gy to each parotid, mean dose of <50 Gy to cochlea 
and mean dose <60 Gy to TMJ. Inverse planning was 
performed using Varian Eclipse Treatment Planning 
Software Version 11. This is shown in Figures 1-3.
Treatment plan was evaluated using dose-volume 
histograms and found the doses as follows: 95% of 
the prescribed dose (57.8 Gy) to PTV60, 100% of the 
prescribed dose (50 Gy) to PTV50, maximum dose of 
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Figure 1: Axial CT image of the neck showing CTV60 (tumour bed only) and CTV50 (sub-clinical disease and neck nodes)
Figure 2: Axial CT image of lower neck with PTV60 (3mm margin to CTV60)
Figure 3: Axial CT image of lower neck with PTV50 (3mm margin to CTV50)
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41 Gy to brainstem, maximum point dose of 43 Gy to 
spinal cord and mean dose of 26 Gy to parotid.
This patient completed the treatment in 6 weeks without 
any interruption weekly clinical assessment was done 
during the treatment for this patient, and he was assessed 
for the acute toxicity defined as side effects occurring 
during radiotherapy. This assessment included the grading 
of side effects according to common toxicity criteria 
version 3. He was assessed in the clinic at 6-week post 
radiotherapy. Acute skin toxicity and mucositis had settled 
and there was no xerostomia. Physical examination 
revealed no local or regional recurrence.
This concludes that simultaneous integrated boost intensity-
modulated radiotherapy technique allowed the treatment 
to be completed with higher doses to the target volumes 
sparing OAR with reduced acute toxicity profile. The patient 
returned to a good quality of life early with no xerostomia.
Abbreviations: 
CT: Computed tomography
CTV: Clinical Tumour Volume receiving 50 or 60 grays
DVH: Dose volume histograms
IMRT: Intensity modulated radiation therapy
OAR: Organ at risk
PTV: Planning Tumour Volume receiving 50 or 60 grays
TMJ: Temporomandibular joint
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